

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

CORRIGENDUM TO FULL YEAR FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to the Company's full year financial statements and dividend announcement released on 31 March 2023 (Announcement Reference: SG230331OTHRH7KQ) (the “**Full Yearly Results Announcement**”).

2. CORRIGENDUM TO THE FULL YEARLY RESULTS ANNOUNCEMENT

The Board refers to Note 24 on page 24 of the Full Yearly Results Announcement in relation to the dividend declared for the financial year ended 31 December 2022 and wishes to inform that due to an inadvertent typographical error, the first paragraph should be corrected to read as follows (with amendments in **bold, underline and deletions in strikethrough**):

*“The Directors propose to seek approval from the shareholders of the Company (the Shareholders”) for declaring a final dividend of **RMB 866,256,245.12** ~~RMB 8,662,562,451.2~~ on the basis of RMB 11.2 for every 10 shares in the capital of the Company. Such proposed declaration of dividends will be subject to approval by Shareholders at the forthcoming annual general meeting to be held on 15 May 2023, and thus has not been included as a liability in these condensed consolidated interim financial statements of the Company and/or Group. Upon obtaining the Shareholders’ approval, the proposed dividend is payable in respect of all issued ordinary shares in the capital of the Company as at the end of the FY2022.”*

Save as disclosed above, all other information contained in the Full Yearly Results Announcement remains unchanged.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
4 April 2023